Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders

Yesterday, March 21, 2016, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $28.00 to $5,401,379.46.

Highlighted Stocks Traded by Insiders:

Flamel Technologies (FLML) - FREE Research Report

Anderson Michael S, who is Chief Executive Officer at Flamel Technologies, bought 5,000 shares at $11.04 on March 21, 2016. Following this transaction, the Chief Executive Officer owned 129,250 shares meaning that the stake was boosted by 4.02% with the 5,000-share transaction.

Hatten Sandra L, who is Sr. VP, Quality & Reg Affairs at Flamel Technologies, bought 3,000 shares at $11.01 on March 21, 2016. Following this transaction, the Sr. VP, Quality & Reg Affairs owned 3,000 shares meaning that the stake was boosted by 100% with the 3,000-share transaction.

The shares most recently traded at $11.07, up $0.06, or 0.54% since the insider transaction.

The average volume for Flamel Technologies has been 339,300 shares per day over the past 30 days. Flamel Technologies has a market cap of $435.3 million and is part of the health care sector and drugs industry. Shares are down 8.35% year-to-date as of the close of trading on Monday.

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology primarily in the United States and Europe. The company has a P/E ratio of 11.9. Currently, there are 4 analysts who rate Flamel Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLML - FREE

TheStreet Quant Ratings rates Flamel Technologies as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full Flamel Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Willis Lease Finance (WLFC) - FREE Research Report

Forsyth Bradley Stewart, who is Shareholder at Willis Lease Finance, sold 1,286 shares at $22.19 on March 21, 2016. Following this transaction, the Shareholder owned 18,988 shares meaning that the stake was reduced by 6.34% with the 1,286-share transaction.

The shares most recently traded at $22.19, up $0.00, or 0.01% since the insider transaction. Historical insider transactions for Willis Lease Finance go as follows:

  • 4-Week # shares bought: 180
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 180
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 180
  • 24-Week # shares sold: 3,000

The average volume for Willis Lease Finance has been 13,400 shares per day over the past 30 days. Willis Lease Finance has a market cap of $169.1 million and is part of the services sector and diversified services industry. Shares are up 10.1% year-to-date as of the close of trading on Monday.

Willis Lease Finance Corporation, together with its subsidiaries, leases commercial aircraft engines and other aircraft-related equipment to air carriers, manufacturers, and overhaul/repair facilities worldwide. It operates through two segments, Equipment Leasing and Spare Parts Sales. The company has a P/E ratio of 23.9. Currently, there are no analysts who rate Willis Lease Finance a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WLFC - FREE

TheStreet Quant Ratings rates Willis Lease Finance as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and growth in earnings per share. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Willis Lease Finance Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Antares Pharma (ATRS) - FREE Research Report

Samson Marvin, who is Director at Antares Pharma, bought 50,000 shares at $0.72 on March 21, 2016. Following this transaction, the Director owned 102,778 shares meaning that the stake was boosted by 94.74% with the 50,000-share transaction.

Jacob Leonard S, who is Director at Antares Pharma, bought 50,000 shares at $0.72 on March 21, 2016. Following this transaction, the Director owned 218,885 shares meaning that the stake was boosted by 29.61% with the 50,000-share transaction.

Gonella Jacques, who is Director at Antares Pharma, bought 100,000 shares at $0.72 on March 21, 2016. Following this transaction, the Director owned 9.1 million shares meaning that the stake was boosted by 1.11% with the 100,000-share transaction.

Gueth Anton, who is Director at Antares Pharma, bought 50,000 shares at $0.72 on March 21, 2016. Following this transaction, the Director owned 302,776 shares meaning that the stake was boosted by 19.78% with the 50,000-share transaction.

Garrity Thomas J, who is Director at Antares Pharma, bought 30,000 shares at $0.72 on March 21, 2016. Following this transaction, the Director owned 160,213 shares meaning that the stake was boosted by 23.04% with the 30,000-share transaction.

Fickenscher James E, who is Senior Vice President & CFO at Antares Pharma, bought 135,000 shares at $0.72 on March 21, 2016. Following this transaction, the Senior Vice President & CFO owned 270,216 shares meaning that the stake was boosted by 99.84% with the 135,000-share transaction.

The shares most recently traded at $0.77, up $0.05, or 6.49% since the insider transaction. Historical insider transactions for Antares Pharma go as follows:

  • 4-Week # shares bought: 60,000
  • 4-Week # shares sold: 23,500
  • 12-Week # shares bought: 60,000
  • 12-Week # shares sold: 23,500
  • 24-Week # shares bought: 60,000
  • 24-Week # shares sold: 23,500

The average volume for Antares Pharma has been 979,400 shares per day over the past 30 days. Antares Pharma has a market cap of $113.0 million and is part of the health care sector and health services industry. Shares are down 33.96% year-to-date as of the close of trading on Monday.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. Currently, there are 4 analysts who rate Antares Pharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATRS - FREE

TheStreet Quant Ratings rates Antares Pharma as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Antares Pharma Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home